Bladder cancer is a malignant tumor originating from the urothelium in the bladder tissue caused by the uncontrolled abnormal proliferation of bladder lining cells. It is one of the most common malignant tumors of the urinary system, ranked 7th among male malignant tumors, and is also a common malignant tumor among females¹.
Based on whether the tumor invades the bladder muscle, bladder cancer can be divided into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC).
Unmet Clinical Needs
Limitations of Traditional Surgical Treatment
Postoperative adjuvant intravesical therapy, including intravesical chemotherapy or Bacille Calmette-Guerin (BCG):
APL-1202 is the world’s first oral targeted NMIBC therapy that has entered the pivotal phase II clinical trial. It is expected to become the first second-line treatment option for intermediate- and high-risk chemotherapy-relapsed NMIBC patients.
Phase II clinical trial results show that APL-1202 is significantly more effective than the current chemotherapy infusion with good safety.
The convenient oral administration also frees patients from the pain of intravesical infusion.
APL-1706 is the only approved diagnostic imaging agent to support detection or surgery of patients with bladder cancer. In combination with Blue Light Cystoscopy, it can effectively improve the detection rate of non-muscle invasive bladder cancer (NMIBC), especially carcinoma in situ, enable better TURBT procedures and reduce recurrences.
- The only approved diagnostic imaging agent to support detection or surgery of patients with bladder cancer.
- Approved and launched on market in over 30 countries.
- Listed in the NMIBC guidelines as a first-line treatment in both US and Europe.
Introducing APLD-2101 from Uroviu, a single-use endoscopy product for diagnosing bladder diseases.
Provide full-range solutions for doctors and patients by integrating innovative products, covering bladder cancer diagnosis, treatment, and patient surveillance.
High Market Demand
New Bladder Cancer Patients Worldwide (x1,000)
New Bladder Cancer Patients in China (x1,000)
Accounts for 75% of bladder cancer patients.
High recurrence rate after surgery, at about 60% within five years.
Data source: Frost & Sullivan